Form 4: HOOKIPA Pharma CFO Sells Shares for Tax Obligations

HOOKIPA Pharma Inc.'s EVP and CFO, Mary Theresa Coelho, sold 13,609 shares of common stock at $0.92 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Mary Theresa Coelho, Executive Vice President and Chief Financial Officer, and a Director of HOOKIPA Pharma Inc., reported a transaction.
• On July 22, 2025, 13,609 shares of HOOKIPA Pharma Inc. common stock were sold.
• The sale price for the common stock was $0.92 per share.
• This transaction was executed as a "sell to cover" arrangement to fulfill tax withholding obligations triggered by the vesting of restricted stock units that were granted on July 22, 2024.
• The sale was explicitly stated as not being a discretionary trade by the reporting person.
• Following this transaction, Mary Theresa Coelho beneficially owns 56,266 shares of HOOKIPA Pharma Inc. common stock.

Sentiment

Score: 7

Explanation: The transaction is a routine "sell to cover" for tax purposes following RSU vesting, which is a common and expected event for executive compensation. It does not indicate a change in management's sentiment towards the company's prospects.

Positives

• The sale was non-discretionary, specifically for tax withholding purposes, and does not reflect a change in management's sentiment towards the company's future.
• The underlying event was the vesting of restricted stock units, indicating compensation and retention of a key executive.

Negatives

• Insider ownership decreased by 13,609 shares of common stock.

Future Outlook

NA

Management Comments

• This sale was affected pursuant to a "sell to cover" arrangement adopted by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units granted on July 22, 2024 and does not represent a discretionary trade by the Reporting Person.

Industry Context

NA

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature of the sale mitigates any negative signal.
• Employees: The vesting of restricted stock units represents a positive compensation event for the executive.

Key Dates

Recommendation

This Form 4 reports a routine "sell to cover" transaction by an executive to satisfy tax obligations upon the vesting of restricted stock units. It does not reflect a discretionary sale based on the executive's view of the company's future prospects. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation.

Keywords

HOOKIPA Pharma, HOOK, Form 4, insider transaction, stock sale, executive compensation, restricted stock units, RSU, tax withholding